Health Care Supplies

Merit Medical

Jason Bednar Maintains Buy Rating for Merit Medical Systems

U.S. Bank Securities Reiterates Hold Rating and Downgrades Target Price for Merit Medical Systems

Merit Medical released FY2026 Q1 earnings on April 30 After-Market EST, actual revenue USD 381.88 M (forecast USD 377.6 M), actual EPS USD 0.68 (forecast USD 0.4862)

Merit Medical Systems Reports Q1 Earnings Per Share Above Estimates

Merit Medical to Release FY2026 Q1 Earnings on April 30 After-Market EST, Forecast Revenue USD 377.61 M, EPS USD 0.4862

FDA Lists Merit Medical Systems Recall as High Risk

Merit Medical released FY2025 Q4 earnings on February 24 After-Market (EST), actual revenue USD 393.94 M (forecast USD 390.92 M), actual EPS USD 0.6404 (forecast USD 0.5914)

Merit Medical released FY2025 earnings on February 24 After-Market EST, actual revenue USD 1.516 B (forecast USD 1.511 B), actual EPS USD 2.13 (forecast USD 2.0942)

Merit Medical to Release FY2025 Q4 Earnings on February 24 After-Market EST, Forecast Revenue USD 390.92 M, EPS USD 0.5914

Merit Medical Systems Inc. Chairman Sells Company Shares

Merit Medical Updates Commercial Strategy for WRAPSODY Stent in U.S.

Merit Medical released FY2025 9 Months Earnings on October 30 After-Market EST, with actual revenue of USD 1.122 B and EPS of USD 1.49

Merit Medical released FY2025 Q3 earnings on October 30 After-Market EST, actual revenue USD 384.16 M (forecast USD 371.74 M), actual EPS USD 0.46 (forecast USD 0.47)

Merit Medical to Release FY2025 Q3 Earnings on October 30 After-Market EST, Forecast Revenue USD 371.69 M, EPS USD 0.47

Petusky Recommends Merit Medical Systems with Upside Potential

Merit Medical Updates 2025 Fiscal Year Earnings Guidance

Merit Announces Acquisition of Biolife and Appointment of New CEO

Merit Medical released FY2025 Q2 earnings on July 30 After-Market EST, actual revenue USD 382.46 M (forecast USD 375.03 M), actual EPS USD 0.54 (forecast USD 0.5371)

Merit Medical released FY2025 Semi-Annual earnings on July 30 After-Market (EST), actual revenue USD 737.81M, actual EPS USD 1.03

Merit Medical Systems Posts Q2 Earnings Beat

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

MMSI

INSP

Non-Invasive Monitoring Systems, Inc. has announced a $200,000 promissory note with Frost Gamma Investments Trust and a $100,000 note with its Chairman, Jane Hsiao, both maturing on June 30, 2026, at an 11% interest rate. This insider financing highlights the company's reliance on major shareholders for short-term liquidity, indicating a close alignment between management and capital structure. The company operates in the medical technology sector, with significant insider ownership.

Tip Ranks

Inspire Medical

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

SPDR S&P Health Equip

iShares US Medical Devices

Non-Invasive Monitoring Secures Insider-Funded Short-Term Financing

Merit Medical Systems (MMSI) experienced significant insider trading on May 11, 2026, with Chief Legal Officer Brian G. Lloyd purchasing 2,000 shares for $125,240, indicating confidence in the company. Conversely, Director Lynne Ward sold 5,000 shares for $313,000. Despite strong Q1 results, analysts have trimmed price targets due to sector-wide issues and governance concerns. Spark's AI Analyst rates MMSI as Neutral, citing solid financial performance but weak technical conditions and a high valuation. The stock has declined 30.49% year-to-date, with a market cap of $3.66B.

Insider Shake-Up at Merit Medical Systems as Top Executives Trade Shares

Piper Sandler analyst Jason Bednar maintained a Buy rating on Merit Medical Systems (MMSI) with a price target of $96.00. Bednar, who focuses on the Healthcare sector, has an average return of -5.7% and a 37.06% success rate on his stock recommendations. Merit Medical also received a Buy rating from Barrington’s Michael Petusky, while Bank of America Securities reiterated a Hold rating on the same day.

Piper Sandler Cos

ICU Medical

Novocure

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Piper Sandler Sticks to Their Buy Rating for Merit Medical Systems (MMSI)

Merit Medical to Participate in the Bank of America Healthcare Conference | MMSI Stock News

StockTitan

Merit Medical to Participate in the Bank of America Healthcare Conference | MMSI Stock News

Merit Medical Systems (NASDAQ:MMSI) reached a new 12-month low of $61.31 after Canaccord Genuity downgraded its price target from $90 to $85, maintaining a buy rating. The stock traded at $61.89 with a volume of 2,526,188 shares. Analysts have mixed ratings, with eight recommending buy and three hold. The company reported a Q1 EPS of $0.94, exceeding estimates, and a revenue of $381.88 million, up 7.4% year-over-year. Merit Medical has a market cap of $3.70 billion and a consensus price target of $92.80.

Market Beat

Citigroup

JPMorgan Chase

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Merit Medical Systems (NASDAQ:MMSI) Reaches New 12-Month Low Following Analyst Downgrade

Merit Medical (MMSI) has raised concerns regarding its revised executive pay agreements, which may lead to increased compensation obligations and corporate governance scrutiny. The changes could dilute shareholder value if performance targets are not met. Concentrating retention incentives among a small leadership group raises pay-for-performance alignment issues and succession risks. Investors may also worry about the impact of these arrangements on M&A flexibility due to potential severance costs. The average stock price target for MMSI is $87.50, indicating a 41.11% upside potential.

Merit Medical’s Revised Executive Pay Deals Raise Dilution, Governance and M&A Flexibility Concerns

Merit Medical Systems shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.

benzinga_article

Merit Medical(MMSI.US)

Non-Invasive Monitoring Secures Insider-Funded Short-Term Financing

Insider Shake-Up at Merit Medical Systems as Top Executives Trade Shares

Piper Sandler Sticks to Their Buy Rating for Merit Medical Systems (MMSI)

Merit Medical to Participate in the Bank of America Healthcare Conference | MMSI Stock News

Merit Medical Systems (NASDAQ:MMSI) Reaches New 12-Month Low Following Analyst Downgrade

Merit Medical’s Revised Executive Pay Deals Raise Dilution, Governance and M&A Flexibility Concerns

Merit Medical Systems shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.